Trial Profile
Phase I trial of sGC 1061 as a potential therapy for Alzheimer's disease and age-related cognitive impairment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2012
Price :
$35
*
At a glance
- Drugs SGC 1061 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; Pharmacokinetics
- 18 Jul 2012 New trial record